Accessibility Statement Skip Navigation
  • Resources
  • Investor Relations
  • Journalists
  • Agencies
  • Client Login
  • Send a Release
Return to PR Newswire homepage
  • News
  • Products
  • Contact
Search
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News Releases view all

    • News in Focus
        • Browse News Releases

        • All News Releases
        • All Public Company
        • English-only
        • News Releases Overview

        • Multimedia Gallery

        • All Multimedia
        • All Photos
        • All Videos
        • Multimedia Gallery Overview

        • Trending Topics

        • All Trending Topics
    • Business & Money
        • Auto & Transportation

        • Aerospace, Defense
        • Air Freight
        • Airlines & Aviation
        • Automotive
        • Maritime & Shipbuilding
        • Railroads and Intermodal Transportation
        • Supply Chain/Logistics
        • Transportation, Trucking & Railroad
        • Travel
        • Trucking and Road Transportation
        • Auto & Transportation Overview

        • View All Auto & Transportation

        • Business Technology

        • Blockchain
        • Broadcast Tech
        • Computer & Electronics
        • Computer Hardware
        • Computer Software
        • Data Analytics
        • Electronic Commerce
        • Electronic Components
        • Electronic Design Automation
        • Financial Technology
        • High Tech Security
        • Internet Technology
        • Nanotechnology
        • Networks
        • Peripherals
        • Semiconductors
        • Business Technology Overview

        • View All Business Technology

        • Entertain­ment & Media

        • Advertising
        • Art
        • Books
        • Entertainment
        • Film and Motion Picture
        • Magazines
        • Music
        • Publishing & Information Services
        • Radio & Podcast
        • Television
        • Entertainment & Media Overview

        • View All Entertain­ment & Media

        • Financial Services & Investing

        • Accounting News & Issues
        • Acquisitions, Mergers and Takeovers
        • Banking & Financial Services
        • Bankruptcy
        • Bond & Stock Ratings
        • Conference Call Announcements
        • Contracts
        • Cryptocurrency
        • Dividends
        • Earnings
        • Earnings Forecasts & Projections
        • Financing Agreements
        • Insurance
        • Investments Opinions
        • Joint Ventures
        • Mutual Funds
        • Private Placement
        • Real Estate
        • Restructuring & Recapitalization
        • Sales Reports
        • Shareholder Activism
        • Shareholder Meetings
        • Stock Offering
        • Stock Split
        • Venture Capital
        • Financial Services & Investing Overview

        • View All Financial Services & Investing

        • General Business

        • Awards
        • Commercial Real Estate
        • Corporate Expansion
        • Earnings
        • Environmental, Social and Governance (ESG)
        • Human Resource & Workforce Management
        • Licensing
        • New Products & Services
        • Obituaries
        • Outsourcing Businesses
        • Overseas Real Estate (non-US)
        • Personnel Announcements
        • Real Estate Transactions
        • Residential Real Estate
        • Small Business Services
        • Socially Responsible Investing
        • Surveys, Polls and Research
        • Trade Show News
        • General Business Overview

        • View All General Business

    • Science & Tech
        • Consumer Technology

        • Artificial Intelligence
        • Blockchain
        • Cloud Computing/Internet of Things
        • Computer Electronics
        • Computer Hardware
        • Computer Software
        • Consumer Electronics
        • Cryptocurrency
        • Data Analytics
        • Electronic Commerce
        • Electronic Gaming
        • Financial Technology
        • Mobile Entertainment
        • Multimedia & Internet
        • Peripherals
        • Social Media
        • STEM (Science, Tech, Engineering, Math)
        • Supply Chain/Logistics
        • Wireless Communications
        • Consumer Technology Overview

        • View All Consumer Technology

        • Energy & Natural Resources

        • Alternative Energies
        • Chemical
        • Electrical Utilities
        • Gas
        • General Manufacturing
        • Mining
        • Mining & Metals
        • Oil & Energy
        • Oil and Gas Discoveries
        • Utilities
        • Water Utilities
        • Energy & Natural Resources Overview

        • View All Energy & Natural Resources

        • Environ­ment

        • Conservation & Recycling
        • Environmental Issues
        • Environmental Policy
        • Environmental Products & Services
        • Green Technology
        • Natural Disasters
        • Environment Overview

        • View All Environ­ment

        • Heavy Industry & Manufacturing

        • Aerospace & Defense
        • Agriculture
        • Chemical
        • Construction & Building
        • General Manufacturing
        • HVAC (Heating, Ventilation and Air-Conditioning)
        • Machinery
        • Machine Tools, Metalworking and Metallurgy
        • Mining
        • Mining & Metals
        • Paper, Forest Products & Containers
        • Precious Metals
        • Textiles
        • Tobacco
        • Heavy Industry & Manufacturing Overview

        • View All Heavy Industry & Manufacturing

        • Telecomm­unications

        • Carriers and Services
        • Mobile Entertainment
        • Networks
        • Peripherals
        • Telecommunications Equipment
        • Telecommunications Industry
        • VoIP (Voice over Internet Protocol)
        • Wireless Communications
        • Telecommunications Overview

        • View All Telecomm­unications

    • Lifestyle & Health
        • Consumer Products & Retail

        • Animals & Pets
        • Beers, Wines and Spirits
        • Beverages
        • Bridal Services
        • Cannabis
        • Cosmetics and Personal Care
        • Fashion
        • Food & Beverages
        • Furniture and Furnishings
        • Home Improvement
        • Household, Consumer & Cosmetics
        • Household Products
        • Jewelry
        • Non-Alcoholic Beverages
        • Office Products
        • Organic Food
        • Product Recalls
        • Restaurants
        • Retail
        • Supermarkets
        • Toys
        • Consumer Products & Retail Overview

        • View All Consumer Products & Retail

        • Entertain­ment & Media

        • Advertising
        • Art
        • Books
        • Entertainment
        • Film and Motion Picture
        • Magazines
        • Music
        • Publishing & Information Services
        • Radio & Podcast
        • Television
        • Entertainment & Media Overview

        • View All Entertain­ment & Media

        • Health

        • Biometrics
        • Biotechnology
        • Clinical Trials & Medical Discoveries
        • Dentistry
        • FDA Approval
        • Fitness/Wellness
        • Health Care & Hospitals
        • Health Insurance
        • Infection Control
        • International Medical Approval
        • Medical Equipment
        • Medical Pharmaceuticals
        • Mental Health
        • Pharmaceuticals
        • Supplementary Medicine
        • Health Overview

        • View All Health

        • Sports

        • General Sports
        • Outdoors, Camping & Hiking
        • Sporting Events
        • Sports Equipment & Accessories
        • Sports Overview

        • View All Sports

        • Travel

        • Amusement Parks and Tourist Attractions
        • Gambling & Casinos
        • Hotels and Resorts
        • Leisure & Tourism
        • Outdoors, Camping & Hiking
        • Passenger Aviation
        • Travel Industry
        • Travel Overview

        • View All Travel

    • Policy & Public Interest
        • Policy & Public Interest

        • Advocacy Group Opinion
        • Animal Welfare
        • Congressional & Presidential Campaigns
        • Corporate Social Responsibility
        • Domestic Policy
        • Economic News, Trends, Analysis
        • Education
        • Environmental
        • European Government
        • FDA Approval
        • Federal and State Legislation
        • Federal Executive Branch & Agency
        • Foreign Policy & International Affairs
        • Homeland Security
        • Labor & Union
        • Legal Issues
        • Natural Disasters
        • Not For Profit
        • Patent Law
        • Public Safety
        • Trade Policy
        • U.S. State Policy
        • Policy & Public Interest Overview

        • View All Policy & Public Interest

    • People & Culture
        • People & Culture

        • Aboriginal, First Nations & Native American
        • African American
        • Asian American
        • Children
        • Diversity, Equity & Inclusion
        • Hispanic
        • Lesbian, Gay & Bisexual
        • Men's Interest
        • People with Disabilities
        • Religion
        • Senior Citizens
        • Veterans
        • Women
        • People & Culture Overview

        • View All People & Culture

    • Explore Our Platform
    • Plan Campaigns
    • Create with AI
    • Distribute Press Releases
    • Report Results
    • Amplify Content
    • All Products
    • General Inquiries
    • Editorial Bureaus
    • Partnerships
    • Media Inquiries
    • Worldwide Offices
    • Hamburger menu
    • PR Newswire: news distribution, targeting and monitoring
    • Send a Release
      • ALL CONTACT INFO
      • Contact Us

        888-776-0942
        from 8 AM - 10 PM ET

    • Searching for your content...

      No results found. Please change your search terms and try again.

      News Releases

      view all
      Close menu
    • News
    • Products
    • Contact
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      • 3 News in Focus
      • 5 Business & Money
      • 5 Science & Tech
      • 5 Lifestyle & Health
      • 1 Policy & Public Interest
      • 1 People & Culture
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      • Explore Our Platform
      • Plan Campaigns
      • Create with AI
      • Distribute Press Releases
      • Report Results
      • Amplify Content
      • All Products
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      • General Inquiries
      • Editorial Bureaus
      • Partnerships
      • Media Inquiries
      • Worldwide Offices
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      Close submenu (News in Focus) News in Focus
      • Browse News Releases
      • Multimedia Gallery
      • Trending Topics
      Close submenu (Business & Money) Business & Money
      • Auto & Transportation
      • Business Technology
      • Entertain­ment & Media
      • Financial Services & Investing
      • General Business
      Close submenu (Science & Tech) Science & Tech
      • Consumer Technology
      • Energy & Natural Resources
      • Environ­ment
      • Heavy Industry & Manufacturing
      • Telecomm­unications
      Close submenu (Lifestyle & Health) Lifestyle & Health
      • Consumer Products & Retail
      • Entertain­ment & Media
      • Health
      • Sports
      • Travel
      Close submenu (Policy & Public Interest) Policy & Public Interest
      • Policy & Public Interest
      Close submenu (People & Culture) People & Culture
      • People & Culture

      BrainStorm Cell Therapeutics Announces Third Quarter 2026 Financial Results and Provides Corporate Update

      BrainStorm Logo

      News provided by

      BrainStorm Cell Therapeutics Inc.

      Nov 16, 2026, 16:01 ET

      Share this article

      Share this article


      NEW YORK, Nov. 16, 2026 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (OTCQB: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today announced financial results for the third quarter ended September 30, 2026, and provided a corporate update.

      "ALS remains a devastating disease with a critical unmet medical need, and patients urgently need new therapeutic options," said Chaim Lebovits, President and Chief Executive Officer of BrainStorm. "We continue to advance and complete the preparations necessary to initiate the Phase 3b ENDURANCE study of NurOwn® in ALS, supported by an FDA-agreed protocol under a Special Protocol Assessment. During the third quarter, we strengthened our leadership with the appointment of Professor Peter J. Pitts as Executive Chairman and broadened our engagement with regulators, potential commercial partners, and investors. Professor Pitts has joined the Company in an active executive capacity and is helping lead the regulatory, operational, partnership, and capital-markets initiatives surrounding the NurOwn program. His experience as a former senior FDA official brings an additional level of regulatory insight and strategic perspective as we prepare to enter this important next phase, and we remain resolute in our commitment to advancing what we believe will be a valuable new therapeutic option for the ALS community."

      Recent Highlights

      Clinical, Scientific, and Regulatory Progress

      • Advancing Phase 3b ENDURANCE Readiness & Constructive Regulatory Backdrop. BrainStorm continues to execute on operational, clinical, and manufacturing activities to support the initiation of the Phase 3b ENDURANCE study of NurOwn® (MSC-NTF cells) in earlier-stage ALS patients under its FDA-agreed Special Protocol Assessment (SPA). The Company also notes the FDA's October 2026 launch of its Rare Disease Framework Initiative, aimed at establishing a more holistic, fit-for-purpose regulatory framework for rare diseases with severe unmet medical needs.
      • Peer-Reviewed Publication on NurOwn®-Derived Extracellular Vesicles (ExMN). BrainStorm's R&D team published "Beneficial effects of small extracellular vesicles derived from MSC-NTF (NurOwn®) cells on lung inflammation and fibrosis" in Stem Cell Research & Therapy, a Q1-ranked journal (DOI: 10.1186/s13287-026-05303-y). The study demonstrated reduced lung inflammation and fibrosis, improved oxygenation, and protection against subsequent lung injury following inhaled pretreatment in preclinical models, supporting the therapeutic and preventive potential of NurOwn®-Derived Extracellular Vesicles (ExMN).

      Corporate and Leadership

      • Appointed Professor Peter J. Pitts as Executive Chairman. On July 28, 2026, BrainStorm announced the appointment of Professor Peter J. Pitts, a former FDA Associate Commissioner and co-founder of the Center for Medicine in the Public Interest, as Executive Chairman and Chief Strategic Regulatory and Policy Officer. Professor Pitts, who joined the Board in May 2026, leads the Company's daily operations, partnerships, investor engagement, and regulatory strategy, focused primarily on advancing the Phase 3b ENDURANCE trial. Professor Jacob Frenkel, a member of BrainStorm's leadership team since 2007 and Board Chairman since 2020, transitioned to Senior Advisor.

      Industry and Investor Engagement

      • Participated in DUPHAT 2026 in Dubai. In August 2026, CEO Chaim Lebovits and Executive Chairman Professor Peter J. Pitts participated in the 31st Dubai International Pharmaceuticals & Technologies Conference and Exhibition (DUPHAT) at the Dubai World Trade Centre. Professor Pitts delivered keynote addresses and moderated panel sessions on regulatory science harmonization and translational collaboration, while BrainStorm's leadership met with regional health regulators, commercial distribution partners, and international investment groups regarding the strategic positioning of NurOwn® and the planned Phase 3b ENDURANCE trial.

      Financial Results for the Third Quarter Ended September 30, 2026

      • Cash, cash equivalents, and restricted cash were approximately $0.35 million as of September 30, 2026, compared to approximately $0.24 million as of September 30, 2025.
      • Research and development expenditures, net, for the third quarter of 2026 were approximately $0.5 million, compared to approximately $0.9 million for the third quarter of 2025.
      • General and administrative expenses for the third quarter of 2026 were approximately $1.09 million, compared to approximately $1.15 million for the third quarter of 2025.
      • Net loss for the third quarter of 2026 was approximately $1.7 million, compared to a net loss of approximately $2.1 million for the third quarter of 2025.
      • Net loss per share for the third quarters of 2026 and 2025 was $(0.14) and $(0.19), respectively.

      U.S. dollars in thousands

      (Except share and per share amounts)










      September 30, 


      December 31, 



      2026


      2025



      Unaudited


      Audited



      U.S. $ in thousands

      ASSETS














      Current Assets:







      Cash and cash equivalents


      $

      163


      $

      29

      Other accounts receivable



      189



      86

      Prepaid expenses and other current assets



      101



      192

      Total current assets


      $

      453


      $

      307








      Long-Term Assets:







      Prepaid expenses and other long-term assets


      $

      26


      $

      25

      Restricted Cash



      185



      247

      Right of use asset



      53



      208

      Property and equipment, net



      123



      235

      Total Long-Term Assets


      $

      387


      $

      715








      Total assets


      $

      840


      $

      1,022








      LIABILITIES AND STOCKHOLDERS' EQUITY (DEFICIT)














      Current Liabilities:







      Accounts payable


      $

      7,473


      $

      7,067

      Accrued expenses



      464



      396

      Short-term loans



      1,875



      967

      Operating lease liability



      56



      208

      Employees related liability



      3,304



      2,369

      Total current liabilities


      $

      13,172


      $

      11,007















      Total liabilities


      $

      13,172


      $

      11,007








      Stockholders' Deficit:







      Stock capital:



      16



      16

      Common stock $0.00005 par value; 250,000,000 shares
      authorized at September 30, 2026 and December 31,
      2025; 14,259,377 and 11,034,775 shares issued and
      outstanding at September 30, 2026 and December 31,
      2025, respectively







      Additional paid-in-capital



      232,426



      227,058

      Treasury stock



      (116)



      (116)

      Accumulated deficit



      (244,658)



      (236,943)

      Total stockholders' deficit


      $

      (12,332)


      $

      (9,985)








      Total liabilities and stockholders' deficit


      $

      840


      $

      1,022

      The accompanying notes are an integral part of the consolidated financial statements.

      BRAINSTORM CELL THERAPEUTICS INC. AND SUBSIDIARIES

      INTERIM CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS (UNAUDITED)


      U.S. dollars in thousands

      (Except share and per share amounts)
















      Nine months ended


      Three months ended



      September 30, 


      September 30, 



      2026


      2025


      2026


      2025



      Unaudited


      Unaudited

      Operating expenses:


























      Research and development, net


      $

      2,248


      $

      3,323


      $

      523


      $

      899

      General and administrative



      5,026



      4,386



      1,092



      1,148














      Operating loss



      (7,274)



      (7,709)



      (1,615)



      (2,047)














      Financial income (expense), net



      (441)



      (343)



      (118)



      (59)














      Gain (loss) on change in
      fair value of Warrants
      liability



      -



      179



      -



      -














      Net loss


      $

      (7,715)


      $

      (7,873)


      $

      (1,733)


      $

      (2,106)














      Basic and diluted net loss
      per share from continuing
      operations


      $

      (0.68)


      $

      (0.91)


      $

      (0.14)


      $

      (0.19)














      Weighted average number
      of shares outstanding used
      in computing basic and
      diluted net loss per share



      11,354,405



      8,673,908



      11,983,241



      11,008,047

      About NurOwn®

      The NurOwn® technology platform (autologous MSC-NTF cells) represents a promising investigational therapeutic approach to targeting disease pathways important in neurodegenerative disorders. MSC-NTF cells are produced from autologous, bone marrow-derived mesenchymal stem cells (MSCs) that have been expanded and differentiated ex vivo. MSCs are converted into MSC-NTF cells by growing them under patented conditions that induce the cells to secrete high levels of neurotrophic factors (NTFs). Autologous MSC-NTF cells are designed to effectively deliver multiple NTFs and immunomodulatory cytokines directly to the site of damage to elicit a desired biological effect and ultimately slow or stabilize disease progression.

      About BrainStorm Cell Therapeutics Inc.

      BrainStorm Cell Therapeutics Inc. (OTCQB: BCLI) is a leading developer of autologous adult stem cell therapies for debilitating neurodegenerative diseases. The company's proprietary NurOwn® platform uses autologous mesenchymal stem cells (MSCs) to produce neurotrophic factor-secreting cells (MSC-NTF cells), designed to deliver targeted biological signals that modulate neuroinflammation and promote neuroprotection.

      NurOwn® is BrainStorm's lead investigational therapy for amyotrophic lateral sclerosis (ALS) and has received Orphan Drug designation from both the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA). A Phase 3 trial in ALS (NCT03280056) has been completed, and a second Phase 3b trial is set to launch under a Special Protocol Assessment (SPA) agreement with the FDA. The NurOwn clinical program has generated valuable insights into ALS disease biology, including pharmacogenomic response associated with the UNC13A genotype, biomarker data collected at seven longitudinal time points, and a comprehensive analysis of the "Floor Effect," a critical challenge in measuring clinical outcomes in advanced ALS. BrainStorm has published its findings in multiple peer-reviewed journals. In addition to ALS, BrainStorm has completed a Phase 2 open-label multicenter trial (NCT03799718) of MSC-NTF cells in progressive multiple sclerosis (MS), supported by a grant from the National MS Society. BrainStorm is also advancing a proprietary, allogeneic exosome-based platform designed to deliver therapeutic proteins and nucleic acids. The company recently received a Notice of Allowance from the U.S. Patent and Trademark Office for a foundational patent covering its exosome technology, further strengthening BrainStorm's growing IP portfolio in this emerging area of regenerative medicine. To learn more, visit www.brainstorm-cell.com.

      Notice Regarding Forward-Looking Statements

      This press release contains "forward-looking statements" that are subject to substantial risks and uncertainties, including statements regarding meetings with the U.S. Food and Drug Administration (FDA), the Special Protocol Assessment (SPA), the clinical development of NurOwn as a therapy for the treatment of ALS, the future availability of NurOwn to patients, and the future success of BrainStorm. All statements, other than statements of historical fact, contained in this press release are forward-looking statements. Forward-looking statements contained in this press release may be identified by the use of words such as "anticipate," "believe," "contemplate," "could," "estimate," "expect," "intend," "seek," "may," "might," "plan," "potential," "predict," "project," "target," "aim," "should," "will", "would," or the negative of these words or other similar expressions, although not all forward-looking statements contain these words. Forward-looking statements are based on BrainStorm's current expectations and are subject to inherent uncertainties, risks and assumptions that are difficult to predict. These potential risks and uncertainties include, without limitation, management's ability to successfully achieve its goals, BrainStorm's ability to raise additional capital, BrainStorm's ability to continue as a going concern, prospects for future regulatory approval of NurOwn, whether BrainStorm's future interactions with the FDA will have productive outcomes, and other factors detailed in BrainStorm's annual report on Form 10-K and quarterly reports on Form 10-Q available at

      http://www.sec.gov. These factors should be considered carefully, and readers should not place undue reliance on BrainStorm's forward-looking statements. The forward-looking statements contained in this press release are based on the beliefs, expectations, and opinions of management as of the date of this press release. BrainStorm does not assume any obligation to update forward-looking statements to reflect actual results or assumptions if circumstances or management's beliefs, expectations or opinions should change, unless otherwise required by law. Although BrainStorm believes that the expectations reflected in the forward-looking statements are reasonable, the Company cannot guarantee future results, levels of activity, performance, or achievements.

      CONTACTS

      Investors:

      Michael Wood
      Phone: +1 646-597-6983
      [email protected]

      Media:

      Uri Yablonka, Chief Business Officer
      Phone: +1 917-284-2911
      [email protected]

      SOURCE BrainStorm Cell Therapeutics Inc.

      Modal title

      Also from this source

      BrainStorm Executive Leadership to Participate in DUPHAT 2026; Executive Chairman Peter J. Pitts Invited to Deliver Two Keynote Addresses and Moderate Panel Sessions

      BrainStorm Executive Leadership to Participate in DUPHAT 2026; Executive Chairman Peter J. Pitts Invited to Deliver Two Keynote Addresses and Moderate Panel Sessions

      BrainStorm Cell Therapeutics Inc. (OTCQB: BCLI) ("BrainStorm" or the "Company"), a developer of cell therapies for neurodegenerative diseases, today...

      BrainStorm Cell Therapeutics Announces Second Quarter 2026 Financial Results and Provides Corporate Update

      BrainStorm Cell Therapeutics Announces Second Quarter 2026 Financial Results and Provides Corporate Update

      BrainStorm Cell Therapeutics Inc. (OTCQB: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today announced...

      More Releases From This Source

      Explore

      Biotechnology

      Biotechnology

      Earnings

      Earnings

      News Releases in Similar Topics

      Contact PR Newswire

      • Call PR Newswire at 888-776-0942
        from 8 AM - 9 PM ET
      • Chat with an Expert
      • General Inquiries
      • Editorial Bureaus
      • Partnerships
      • Media Inquiries
      • Worldwide Offices

      Products

      • Explore Our Platform
      • Plan Campaigns
      • Create with AI
      • Distribute Press Releases
      • Report Results
      • Amplify Content

      About

      • About PR Newswire
      • About Cision
      • Careers
      • Accessibility Statement
      • APAC
      • APAC - Simplified Chinese
      • APAC - Traditional Chinese
      • Brazil
      • Canada
      • Czech
      • Denmark
      • Finland
      • France
      • Germany
      • India
      • Indonesia
      • Israel
      • Italy
      • Japan
      • Korea
      • Mexico
      • Middle East
      • Middle East - Arabic
      • Netherlands
      • Norway
      • Poland
      • Portugal
      • Russia
      • Slovakia
      • Spain
      • Sweden
      • United Kingdom
      • Vietnam

      My Services

      • All New Releases
      • Platform Login
      • Data Privacy

      Do not sell or share my personal information:

      • Submit via [email protected] 
      • Call Privacy toll-free: 877-297-8921

      Contact PR Newswire

      Products

      About

      My Services
      • All News Releases
      • Platform Login
      • ProfNet
      Call PR Newswire at
      888-776-0942
      • Terms of Use
      • Privacy Policy
      • Information Security Policy
      • Site Map
      • RSS
      • Cookies
      Copyright © 2026 Cision US Inc.